Diasorin SpAWBO:DIAS -0.83%74 Debt-to-EBITDA is 1.24 as of Dec. 2025, which is 629% above its 10-year median of 0.17. GuruFocus rates WBO:DIAS with a GF Score™ of 74/100 and a GF Value™ of €89.83 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 112 Medical Diagnostics & Research companies, Diasorin SpA ranks worse than 50.89% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Diasorin SpA's Debt-to-EBITDA or its related term are showing as below:
WBO:DIAS'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.08 Med: 0.17 Max: 2.3
Current: 2.3
During the past 13 years, the highest Debt-to-EBITDA Ratio of Diasorin SpA was 2.30. The lowest was 0.08. And the median was 0.17.
WBO:DIAS's Debt-to-EBITDA is ranked worse than 50.89% of 112
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.29
vs WBO:DIAS: 2.30
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Diasorin SpA Debt-to-EBITDA Related Terms
Diasorin SpA Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Diasorin SpA's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:DIAS vs TMO, DHR, IDXX: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Diasorin SpA's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diasorin SpA Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Diasorin SpA's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Dec. 2025) EBITDA data.
Diasorin SpA (WBO:DIAS) has a Debt-to-EBITDA of 1.24 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Diasorin SpA. This is 629% above median its historical median of 0.17. Over the past decade, Diasorin SpA's Debt-to-EBITDA has ranged from 0.08 to 2.30. According to the industry distribution chart, Diasorin SpA ranks #57 out of 112 companies in the Medical Diagnostics & Research industry, placing it in the top 50.9%.
Is Diasorin SpA's Debt-to-EBITDA too high?
Diasorin SpA's current Debt-to-EBITDA of 1.24 is 629% above median its 10-year median of 0.17. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 2.30. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.29. Diasorin SpA's value of 1.24 is 45.9% below this industry median. Based on the distribution chart, Diasorin SpA ranks #57 out of 112 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Diasorin SpA has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diasorin SpA ranks #57 out of 112 companies for Debt-to-EBITDA. This places Diasorin SpA in the lower half of its industry. The industry median Debt-to-EBITDA is 2.29. Diasorin SpA's value of 1.24 is 45.9% below this benchmark. Historically, Diasorin SpA's own Debt-to-EBITDA has ranged from 0.08 to 2.30 over the past decade. While the company's 10-year median is 0.17 vs. the industry median of 2.29, Diasorin SpA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.29, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diasorin SpA's current Debt-to-EBITDA of 1.24 is 45.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Diasorin SpA. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diasorin SpA's current Debt-to-EBITDA is 1.24, which is 629% above median its own 10-year median of 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (WBO:DIAS) is currently considered Modestly Undervalued. The stock's GF Value™ is €89.83, compared to a current price of €69.36 — trading 22.8% below its estimated fair value. The current Debt-to-EBITDA is 1.24, which is 629% above median its 10-year median of 0.17 and 45.9% below the Medical Diagnostics & Research industry median of 2.29. Diasorin SpA's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Diasorin SpA (WBO:DIAS), the current Debt-to-EBITDA is 1.24 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diasorin SpA (WBO:DIAS) Overvalued in 2026?
Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued.
The current stock price of €69.36 is trading 22.8% below its estimated GF Value™ of €89.83.
GuruFocus considers Diasorin SpA to be Modestly Undervalued.
Key valuation signals for WBO:DIAS:
Debt-to-EBITDA: 1.24 (629% above median its 10-year median of 0.17)
GF Value™: €89.83 vs. price of €69.36 (22.8% below fair value)
Industry Position: 45.9% below the Medical Diagnostics & Research median (#57 of 112)
No single metric tells the full story. See the WBO:DIAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
74GF Score
Get the complete analysis for WBO:DIAS
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:DIAS has been successfully added to your 
